Physician profile
Glen Eldon Tullous
NPI 1720652167
$3,124.50
in general payments reported to CMS, 2019-2025
41 companies · $933 in 2025
The $933 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.29 · 2022: $176 · 2023: $802 · 2024: $1,138 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,872.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $452.49 | 2022-2025 | |
| Pfizer INC. | $366.51 | 2023-2025 | |
| Novo Nordisk INC | $165.74 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $163.14 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Impulse Dynamics (USA) INC. | $145.03 | 2023-2024 | Optimizer, Optimizer |
| Exact Sciences Corporation | $128.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Scpharmaceuticals INC. | $122.59 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.13 | 2023-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $102.64 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $100.60 | 2023 | Verquvo, Belsomra, Steglatro |
| Boston Scientific Corporation | $91.35 | 2023-2024 | Watchman Flx, Watchman Access System |
| Lilly USA, LLC | $85.20 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $72.76 | 2022-2025 | Repatha, Otezla, Repatha |
| Tactile Systems Technology INC | $72.54 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Astellas Pharma US INC | $71.85 | 2024-2025 | Veozah |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Tullous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.